The impact of serum uric acid on cardiovascular outcomes in the LIFE study.
D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D001262:Atenolol / Q000008:administration & dosage / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D003404:Creatinine / Q000097:blood; D023381:Endpoint Determination; D005260:Female; D005500:Follow-Up Studies; D006454:Hemoglobins; D006801:Humans; D006977:Hypertension, Renal / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D019808:Losartan / Q000008:administration & dosage* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D016016:Proportional Hazards Models; D012307:Risk Factors; D016896:Treatment Outcome; D014527:Uric Acid / Q000097:blood*
D000959:Antihypertensive Agents; D006454:Hemoglobins; D014527:Uric Acid; D001262:Atenolol; D003404:Creatinine; D019808:Losartan